• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:54:46 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G/A 1 ea135738-13ga1eitner_hoth.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) 

     

    HOTH THERAPEUTICS, INC. 

    (Name of Issuer)

     

    COMMON STOCK 

    (Title of Class of Securities)

     

    44148G 10 5 

    (CUSIP Number)

     

    December 31, 2020 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

     

     

     

     

    CUSIP No. 44148G 10 5 

      

    1

    NAME OF REPORTING PERSONS

    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     
    Matthew Eitner

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☐
    (b)
    ☐
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     
     18,750(1)

    6

    SHARED VOTING POWER

     

    0 

    7

    SOLE DISPOSITIVE POWER

     
    18,750(1)

    8

    SHARED DISPOSITIVE POWER

     
    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    18,750(1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     
    0.14% (based on 13,439,229 shares outstanding as of January 7, 2021)

    12

    TYPE OF REPORTING PERSON

     

    IN 

     

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    2

     

      

    Item 1(a).Name of Issuer:

     

    Hoth Therapeutics, Inc., a Nevada corporation (“Issuer”).

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    1 Rockefeller Plaza, Suite 1039, New York, NY 10020.

     

    Item 2(a).Name of Person Filing.

     

    The statement is filed on behalf of Matthew Eitner (the “Reporting Person”).

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    521 Fifth Avenue, 12th Floor, New York, NY 10175

     

    Item 2(c).Citizenship.

     

    The Reporting Person is a citizen of the United States.

     

    Item 2(d).Title of Class of Securities.

     

    Common Stock, par value $0.0001.

     

      Item 2(e). CUSIP Number.

     

    44148G 10 5

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a

     

    (a) ☒ Broker or dealer registered under section 15 of the Act.

     

    Item 4.Ownership.

     

    (a) Amount beneficially owned: 18,750(1)

     

    (b) Percent of class 0.14% (based on 13, 439,229 shares common stock outstanding as of January 7, 2021)

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote: 18,750(1)

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 18,750(1)

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    (1)Represents (i) 15,000 shares of common stock held by Mr. Eitner and  (ii) 3,750 shares of common stock underlying warrants to purchase common stock held by Mr. Eitner.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    3

     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Matthew Eitner
       
    Date: February 16, 2021 /s/ Matthew Eitner
      Matthew Eitner

     

     

    5

     

     

     

    Get the next $HOTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

    MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment. Key Highlights  U.S. Provisional Patents filed expanding HT-001's therapeutic reach.Indications covered:Drug-Induced Hypersensitivity SyndromeRadiotherapy-Induced RashDermatological Conditions Associated with MENIN Inhibitor TherapyMENIN inhibitors are an emerging oncology class with significant promise in acute leukemias and select solid tumors, but treatment-limiting rashes remai

    9/24/25 8:13:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

    NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT achieving key validation milestones, the expansion of its treasury reserve strategy to include Bitcoin, Ethereum, and Solana, and the advancement of its VA obesity program, management emphasized that Hoth is operating from the strongest position in its history. Key Developments Driving M

    9/16/25 8:14:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

    NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi). The submission marks a major regulatory inflection point for Hoth, reinforcing its commitment to a global clinical strategy and unlocking the potential to address a vast oncology supp

    9/10/25 8:29:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    SEC Filings

    View All

    SEC Form 8-K filed by Hoth Therapeutics Inc.

    8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    9/12/25 8:15:26 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    8/22/25 4:15:38 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Hoth Therapeutics Inc.

    10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)

    8/12/25 4:15:47 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/19/24 8:00:03 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb was granted 800,000 shares and covered exercise/tax liability with 310,744 shares, increasing direct ownership by 842% to 547,387 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/28/25 6:48:36 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Camarra Christopher Michael

    3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    5/21/25 5:30:18 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Knie Robb

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    1/15/25 4:15:55 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

    Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

    6/5/25 8:12:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

    1/31/22 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/24 2:47:32 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hoth Therapeutics Inc.

    SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/23 12:55:35 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care